Vernalis plc announces that the FDA has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for...
The FDA has approved the New Drug Application (NDA) for Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) extended-release oral suspension,...
These guidelines incorporate the recent advances in chronic cough pathophysiology, diagnosis and treatment. The concept of cough hypersensitivity has allowed an umbrella term that explains the exquisite sensitivity of patients to external stimuli such a cold air, perfumes, smoke and bleach.
Vernalis plc and Tris Pharma, Inc. announce that the FDA has accepted the CCP-07 New Drug Application (�NDA�) for full...
Containing relevant Learning Zones, guidelines, trials and news.
For the relief of symptoms of colds and influenza, including the relief of aches and pains, sore throat, headache, nasal congestion, lowering of temperature and chesty coughs.
Background: Gefapixant is an oral P2X3 receptor antagonist that has previously shown efficacy and safety in refractory chronic cough and unexplained chronic cough.
For the symptomatic relief of dry tickly coughs and sore throats.
For the relief of symptoms associated with colds and flu and the pain and congestion of sinusitis, including aches and pains, headache, blocked nose and sore throat, chills, lowering of temperature, and to loosen stubborn mucous and provide relief from chesty coughs.
Merck Inc announced the results from two pivotal Phase III trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of MK 7264 (gefapixant), an investigational, orally administered, selective P2X3 receptor antagonist, for the potential treatment of refractory or unexplained chronic cough.